First Financial Bankshares Inc Buys 2,834 Shares of Johnson & Johnson $JNJ

First Financial Bankshares Inc lifted its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 641,717 shares of the company’s stock after acquiring an additional 2,834 shares during the period. Johnson & Johnson comprises approximately 3.0% of First Financial Bankshares Inc’s holdings, making the stock its 8th largest position. First Financial Bankshares Inc’s holdings in Johnson & Johnson were worth $169,888,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. National Pension Service increased its holdings in Johnson & Johnson by 1.3% in the second quarter. National Pension Service now owns 5,226,968 shares of the company’s stock worth $1,327,493,000 after buying an additional 67,484 shares during the last quarter. IFP Advisors Inc raised its position in shares of Johnson & Johnson by 8.8% in the second quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock valued at $9,844,000 after purchasing an additional 3,133 shares during the period. Elefante Mark B lifted its position in Johnson & Johnson by 9.8% during the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company’s stock worth $7,285,000 after acquiring an additional 2,563 shares during the last quarter. AMG Asset Management Group Inc. lifted its position in shares of Johnson & Johnson by 172.0% during the 3rd quarter. AMG Asset Management Group Inc. now owns 3,852 shares of the company’s stock worth $1,020,000 after purchasing an additional 2,436 shares during the last quarter. Finally, Gradient Investments LLC boosted its position in shares of Johnson & Johnson by 9.9% in the second quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock valued at $38,815,000 after acquiring an additional 13,737 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 1.1%

Shares of NYSE JNJ opened at $282.62 on Tuesday. Johnson & Johnson has a 1 year low of $195.90 and a 1 year high of $290.25. The firm’s 50-day moving average is $267.12 and its 200-day moving average is $250.12. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $680.36 billion, a PE ratio of 42.82, a price-to-earnings-growth ratio of 2.80 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same period in the previous year, the firm posted $2.80 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities analysts expect that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. Johnson & Johnson’s payout ratio is presently 81.21%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Elizabeth Forminard sold 13,072 shares of Johnson & Johnson stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total value of $3,717,546.08. Following the sale, the executive vice president directly owned 16,994 shares of the company’s stock, valued at approximately $4,832,923.66. This trade represents a 43.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent research reports. Johnson Rice downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. Wells Fargo & Company lifted their price objective on Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a report on Friday, October 16th. Argus set a $300.00 target price on shares of Johnson & Johnson in a report on Wednesday, July 29th. Evercore set a $300.00 price objective on shares of Johnson & Johnson in a report on Tuesday, October 20th. Finally, Raymond James Financial set a $280.00 price target on Johnson & Johnson in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $275.92.

Get Our Latest Stock Analysis on JNJ

Trending Headlines about Johnson & Johnson

Here are a few of the latest headlines about JNJ:

  • Positive Sentiment: J&J will pay $2.2 billion upfront for Ollin, with up to about $1.1 billion in additional regulatory and commercial milestone payments. The acquisition adds OLN324, a late-stage antibody being developed for wet age-related macular degeneration and diabetic macular edema, and could complement J&J’s existing eye-care business. J&J bets $2.2B on Ollin’s vision loss drug
  • Positive Sentiment: Blackstone Life Sciences will provide $750 million to fund OLN324’s Phase 3 program, helping support development of the drug while sharing its funding burden. Blackstone Life Sciences Announces $750 Million R&D Funding Agreement
  • Neutral Sentiment: OLN324 is still investigational, so its commercial prospects depend on successful trials, regulatory approval and uptake. The retinal-disease market is crowded and competitive, which could limit eventual returns on the acquisition. J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.